

TOTAL SYNTHESIS OF (+)-MONOMORINE I VIA ASYMMETRIC α -KETONIC CLEAVAGE OF 8-AZABICYCLO[3.2.1]OCTAN-3-ONE


Takefumi MOMOSE,* Naoki TOYOOKA, Sumie SEKI, and Yoshiro HIRAI

Faculty of Pharmaceutical Sciences, Toyama Medical & Pharmaceutical University, 2630 Sugitani, Toyama 930-01, Japan

The total synthesis of (+)-monomorphine I and preparation of *cis*-2,5-difunctionalized pyrrolidines, as a chiral synthon, starting with asymmetric cleavage of the 'fork head' ketone of 8-azabicyclo[3.2.1]octan-3-one are described.


KEYWORDS (+)-monomorphine I; asymmetric α -ketonic cleavage; 'fork head' ketone; asymmetric deprotonation; 8-azabicyclo[3.2.1]octan-3-one; σ -symmetric bicyclic ketone; ant pheromone; σ -symmetric pyrrolidine; ozonolysis

A 2,5-disubstituted pyrrolidine or 2,6-disubstituted piperidine moiety constitutes a large family of naturally occurring alkaloids, many of which display significant biological activities.¹⁾ In a study associated with the asymmetric deprotonation of σ -symmetric bicyclic ketones according to the Koga's method,²⁾ the asymmetric cleavage of the 'fork head' ketone of 9-azabicyclo[3.3.1]nonan-3-one was found to proceed in high enantiomeric excess (ee) to lead to the *cis*-2,6-difunctionalized piperidine derivative.³⁾ We examined the application of this procedure to the 8-azabicyclo[3.2.1]octan-3-one system with a view to obtaining a *cis*-2,5-disubstituted pyrrolidine synthon as a chiral building block for the syntheses of natural products with a pyrrolidine skeleton such as monomorphine I (2)⁴⁾ and indolizidine 223AB. Here we describe the total synthesis of (+)-2,^{5,6,7)} a trail pheromone of the pharaoh ant, *via* a 'chiral pyrrolidine' route starting with the asymmetric cleavage of the azabicyclic 'fork head' ketone and also the synthesis of the σ -symmetric pyrrolidine derivative 3 as a chiral building block.



An *N*-protected 8-azabicyclo[3.2.1]octan-3-one (1) was subjected to the kinetic deprotonation procedure according to the method of Koga²⁾ [chiral base 4, *n*-butyllithium (*n*-BuLi), excess trimethylsilyl chloride (TMSCl)] to afford the corresponding trimethylsilyl enolate 5⁸⁾ in 90% ee⁹⁾ (89% yield) (Chart 1). Ozonolysis of the silyl enol ether 5 and subsequent sodium borohydride reduction followed by esterification of the resulting carboxylic acid afforded the *cis*-2,5-disubstituted pyrrolidine derivative 6, [α]_D²⁶ -12.3° (*c*, 1.24, CHCl₃). Protection of the hydroxyl in 6 with methoxymethyl chloride (MOMCl) followed by reduction with lithium triethylborohydride (Super-Hydride) afforded the alcohol 7 in 84% yield. Compound 7 was converted into the iodide 9, *via* the tosylate 8, which was transformed by the Grignard cross coupling reaction with allylmagnesium chloride in the presence of a copper(I) salt into the olefin 10 in 70% yield. Further carbon-chain elongation of 10 was carried out through removal of the methoxymethyl group and the Swern oxidation of the resulting alcohol followed by the Wittig reaction (propyltriphenylphosphonium bromide, *n*-BuLi) to give the diolefin 11 in 77% yield. Site-selective oxidation of 11 under the Wacker process (O₂, PdCl₂, CuCl) smoothly proceeded to give the ketone 12 in 84% yield. Final hydrogenation of 12 over Pd/C in methanol gave (+)-monomorphine I (2), [α]_D²⁶ + 33.2° (*c* 0.6, hexane), in 70% yield after recrystallization of its

hydrochloride from ether-ethanol, which was identical in its ^1H - and ^{13}C -NMR and mass spectra with an authentic specimen $[[\alpha]_{\text{D}}^{22} + 34.3^\circ (c\ 1.02, \text{hexane})]$.⁶⁾ The present synthesis is the first entry to the indolizidine alkaloid starting from the chiral pyrrolidine synthon.



Reagents and conditions: a) 4, *n*-BuLi, TMSCl-HMPA, -100°C ; b) O_3 , CH_2Cl_2 -MeOH(10:1), -78°C and then NaBH_4 ; c) CH_2N_2 ; d) MOMCl, (iso-Pr)₂EtN; e) Super-Hydride, THF, 0°C ~rt; f) TsCl, pyridine; g) NaI, acetone; h) allylmagnesium chloride, CuI, THF, -78 ~ -36°C ; i) c.HCl, MeOH; j) $(\text{COCl})_2$, DMSO, Et₃N, -78°C ; k) $\text{CH}_3\text{CH}_2\text{CH}=\text{PPh}_3$, 0°C ~rt; l) O_2 , PdCl₂, CuCl; m) 5% Pd/C, MeOH.

Chart 1

To add to the above synthesis, the σ -symmetric pyrrolidine 3 was synthesized from 7 via the following sequences (Chart 2). Treatment of the alcohol 7 with *o*-nitrophenyl selenocyanate followed by oxidation with hydrogen peroxide gave the olefin 13 in 60% yield. Ozonolysis of 13 and subsequent sodium borohydride reduction furnished the pyrrolidine derivative 3¹⁰⁾ in 60% yield.




Chart 2

Compound 3 is a potential chiral building block for the divergent synthesis of both enantiomers of pyrrolidine alkaloids. Further transformations of 3, for example, to (-)-monomorine I and other indolizidine alkaloids are under investigation.

ACKNOWLEDGEMENT We are grateful to Professor K. Koga, Tokyo University, for his useful advice for the preparation and properties of the chiral amine **4**, and indebted to Professor C. Kibayashi, Tokyo College of Pharmacy, for his kindly providing us with the ^1H - and ^{13}C -NMR and mass spectra of (+)-monomorphine I.

REFERENCES AND NOTES

- 1) a) G. M. Strunz and J. A. Findlay, "The Alkaloids," ed. by A. Brossi, Academic Press, New York, 1985, Vol. 26, p. 89; b) G. Massiot and C. Delaude, *ibid.*, 1986, Vol. 27, p. 269; c) A. Numata and T. Ibuka, *ibid.*, 1987, Vol. 31, p. 193.
- 2) R. Shirai, M. Tanaka, and K. Koga, *J. Am. Chem. Soc.*, **108**, 543 (1986).
- 3) T. Momose, N. Toyooka, and Y. Hirai, *Chem. Lett.*, 1990, in press. The work was presented in part at the 79th meeting of Hokuriku Branch, Pharmaceutical Society of Japan, Toyama, Nov. 1989, Abstracts of Papers, p. 3.
- 4) F. J. Ritter, I. E. M. Rotgans, E. Talman, P. E. J. Verwiel, and F. Stein, *Experientia*, **29**, 530 (1973).
- 5) For syntheses of racemic monomorphine I, see: a) J. E. Oliver and P. E. Sonnet, *J. Org. Chem.*, **39**, 2662 (1974); b) P. E. Sonnet and J. E. Oliver, *J. Heterocyclic Chem.*, **12**, 289 (1975); c) P. E. Sonnet, D. A. Natzel, and R. Mendoza, *ibid.*, **16**, 1041 (1979); d) T. L. Macdonald, *J. Org. Chem.*, **45**, 193 (1980); e) R. V. Stevens and A. W. M. Lee, *J. Chem. Soc., Chem. Commun.*, **1982**, 102; f) H. Iida, Y. Watanabe, and C. Kibayashi, *Tetrahedron Lett.*, **27**, 5513 (1986); g) R. Yamaguchi, E. Hata, T. Matsuki, and M. Kawanishi, *J. Org. Chem.*, **52**, 2094 (1987).
- 6) For chiral synthesis of (+)-monomorphine I, see: N. Yamazaki and C. Kibayashi, *Tetrahedron Lett.*, **29**, 5767 (1988).
- 7) For chiral synthesis of (-)-monomorphine I, see: J. Royer and H.-P. Husson, *J. Org. Chem.*, **50**, 670 (1985).
- 8) Satisfactory analytical and spectral data were obtained for all new compounds: for example, for **6**; ^1H -NMR (270 MHz, CDCl_3) δ : 1.60~1.86 (2H, br m), 1.93~2.13 (2H, br m), 2.31~2.60 (1H, br), 2.64~2.80 (1H, br), 3.40~3.70 (4H, br, including at δ 3.56, 3H, br s), 3.79~3.91 (1H, br m), 3.92~4.07 (1H, br), 4.09~4.21 (1H, br, exchangeable with D_2O), 4.25~4.41 (1H, br), 5.11 & 5.16 (2H, AB q, $J=12.0$ Hz), 7.28~7.44 (5H, m). HRMS: Calcd. for $\text{C}_{16}\text{H}_{21}\text{NO}_5$; 307.1419. Found; 307.1459. For **10**; ^1H -NMR (270 MHz, CDCl_3) δ : 1.22~1.47 (3H, m), 1.53~1.75 (1H, m), 1.84~2.20 (6H, m), 3.30 (3H, br s), 3.35~3.50 (1H, br), 3.52~3.77 (1H, br), 3.85 (1H, br), 4.07 (1H, br), 4.60 (2H, br s), 4.92 (1H, d-like, $J=10.1$ Hz), 4.95 (1H, d-like, $J=16.5$ Hz), 5.13 (2H, s), 5.74~5.86 (1H, m), 7.28~7.37 (5H, m). HRMS: Calcd. for $\text{C}_{20}\text{H}_{29}\text{NO}_4$; 347.2097. Found; 347.2140. For **12**; ^1H -NMR (270 MHz, CDCl_3) δ : 0.80~1.10 (3H, br), 1.25~1.43 (1H, m), 1.51~1.74 (5H, m), 1.85~2.15 (7H, m, including at δ 2.10, 3H, br s), 2.44 (2H, br), 3.89 (1H, br m), 4.60 (1H, br m), 5.11 (2H, br s), 5.25 (1H, t-like, $J=8.6$ Hz), 5.34 (1H, br), 7.27~7.38 (5H, m). HRMS: Calcd. for $\text{C}_{21}\text{H}_{29}\text{NO}_3$; 343.2145. Found; 343.2138.
- 9) Determined by HPLC using the chiral column OJ (Daicel Chemical Industries, Ltd.).
- 10) A colorless oil; ^1H -NMR (270 MHz, CDCl_3) δ : 1.92~2.08 (4H, br), 3.30 (3H, s), 3.45~3.65 (3H, brs), 3.77~3.98 (1H, br), 4.00~4.16 (2H, brm), 4.25~4.40 (1H, br, exchangeable with D_2O), 4.50~4.69 (2H, brs), 5.14 & 5.19 (2H, ABq, $J=12.8$ Hz), 7.31~7.38 (5H, m). $[\alpha]_{\text{D}}^{26} -8.3^\circ$ (c 0.78, CHCl_3).

(Received May 28, 1990)